Dr Simon Hart

Dr Simon Hart

Reader in Respiratory Medicine

Faculty and Department

  • Faculty of Health Sciences
  • Hull York Medical School

Summary

Graduated from Edinburgh University and trained in respiratory and general medicine in south-east Scotland. PhD in neutrophil and macrophage biology in the MRC Centre for Inflammation Research, followed by an MRC Clinician Scientist fellowship.

Lead clinician for the Hull interstitial lung disease and Sarcoidosis services. Participates in the acute general medicine rota at Hull Royal Infirmary.

Research interests include the biology of pulmonary fibrosis, interstitial lung diseases, and sarcoidosis.

Deputy Academic Program Training Director, North & East Yorkshire and North Lincolnshire

Year 3 clinical tutor, respiratory medicine

Year 2 respiratory resource session lead

Years 1 and 2 lecturer

SSIP supervisor and abstract reviewer

Hull York Medical School taster sessions for school leavers

Host international elective students at Hull York Medical School

Host work experience students considering applying for Medicine

Former co-lead for academic foundation program at Hull York Medical School

Former chair, Hull York Medical School Academic Progress Committee

Recent outputs

View more outputs

Journal Article

Opioids bring peace to patients with IPF cough

Sykes, D. L., & Hart, S. P. (in press). Opioids bring peace to patients with IPF cough. The lancet. Respiratory medicine, https://doi.org/10.1016/s2213-2600%2823%2900467-8

Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK

Dixon, G., Hague, S., Mulholland, S., Adamali, H., Khin, A. M. N., Thould, H., …Barratt, S. L. (2024). Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK. ERJ Open Research, 10(1), Article 00529-2023. https://doi.org/10.1183/23120541.00529-2023

High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study

Desai, S. R., Desai, S. R., Sivarasan, N., Johannson, K. A., Johannson, K. A., George, P. M., …Inoue, Y. (in press). High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study. The lancet. Respiratory medicine, https://doi.org/10.1016/S2213-2600%2823%2900267-9

Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis

Mohamed, E., Hart, S., & Guinn, B. (in press). Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis. Carcinogenesis, Article bgad091. https://doi.org/10.1093/carcin/bgad091

Examining the relationship between inflammatory biomarkers during COVID-19 hospitalization and subsequent long-COVID symptoms: A longitudinal and retrospective study

Sykes, D. L., Van der Feltz-Cornelis, C. M., Holdsworth, L., Hart, S. P., O'Halloran, J., Holding, S., & Crooks, M. G. (2023). Examining the relationship between inflammatory biomarkers during COVID-19 hospitalization and subsequent long-COVID symptoms: A longitudinal and retrospective study. Immunity, Inflammation and Disease, 11(10), Article e1052. https://doi.org/10.1002/iid3.1052

Research interests

Pulmonary fibrosis

Pulmonary fibrosis is a progressive incurable scarring disease of the lungs that affects about 30,000 people in the UK. Development of effective therapies will depend on understanding the biology of lung scarring.

Platelet biology and lung fibrosis

We have shown that platelets are hyper-active in patients with idiopathic pulmonary fibrosis (IPF). Platelets contain granules rich in growth factors, with the potential to drive fibrosis when platelets are retained and activated in the lungs. We are studying how platelets contribute to pulmonary fibrosis.

Steroids and pulmonary fibrosis

The PANTHER-IPF clinical trial showed for the first time that steroid-containing treatment regimens unfortunately led to worse outcomes for people with IPF. We wish to harness this unique observation to better understand the roles of corticosteroids in the biology of pulmonary fibrosis.

Molecular imaging of the lungs

We are developing novel imaging techniques in pulmonary fibrosis, both in the lab (in collaboration with Hull University PET imaging centre) and in the clinic.

Symptoms and quality of life

We have an ongoing research program into assessing and treating difficult symptoms in pulmonary fibrosis in conjunction with colleagues in palliative medicine at Hull York Medical School.

Sarcoidosis

About 4,500 people in the UK are diagnosed each year with sarcoidosis, a chronic inflammatory disease that affects the lungs, lymph nodes, eyes, and skin, and sometimes the bones, heart and nervous system. Disabling symptoms such as breathlessness and fatigue lead to impaired quality of life, and loss of work and income, and some patients suffer considerable morbidity and premature death. Pathologically, affected tissues are infiltrated by granulomas composed of macrophages and other immune cells. Current treatments such as steroids temporarily suppress the inflammatory response, but side effects can be personally distressing, disfiguring, and dangerous. Thus, it is important to understand the cellular and molecular drivers of persistent and progressive disease so that patients with sarcoidosis have treatment options that improve or control their disease without causing undesirable side effects.

The monocyte/macrophage in sarcoidosis

Recent evidence has highlighted key roles for tissue macrophages and their precursors, blood monocytes, in driving sarcoidosis pathology. We are studying immune responses in the blood and lung tissue of patients with sarcoidosis to help understand how the disease is initiated and perpetuated. We are particularly interested in how abnormal function of regulatory (inhibitory) receptors on blood monocytes leads to an overactive immune response in sarcoidosis.

Thanks to our funders:

SarcoidosisUK

British Lung Foundation

Sir Jules Thorn Charitable Trust

Foundation for Sarcoidosis Research

Boehringer Ingelheim

Chiesi

Lead investigator

Project

Funder

Grant

Started

Status

Project

A cell model for discovering biomarkers and druggable targets for pulmonary fibrosis

Funder

BLF British Lung Foundation

Grant

£79,958.00

Started

1 May 2023

Status

Ongoing

Project

A single arm, open-label exploratory clinical trial of azithromycin in pulmonary sarcoidosis

Funder

SarcoidosisUK

Grant

£59,992.00

Started

1 March 2019

Status

Complete

Project

Development and application of a multi-scale computational model of sarcoidosis to predict therapeutic approaches for non-self-resolving disease

Funder

Foundation for Sarcoidosis Research

Grant

£117,415.00

Started

30 June 2017

Status

Complete

Project

Sir Jules Thorn PhD Scholarship Programme 2016

Funder

Jules Thorn Charity

Grant

£83,999.00

Started

1 September 2016

Status

Complete

Project

Characterisation of monocyte CD200R in pulmonary sarcoidosis

Funder

BLF British Lung Foundation

Grant

£116,317.00

Started

1 March 2016

Status

Complete

Project

ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebocontrolled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£38,885.00

Started

1 August 2019

Status

Complete

Project

SCENIC: Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF)

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£17,918.00

Started

1 May 2019

Status

Complete

Project

ATLAS: A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£5,937.00

Started

1 June 2019

Status

Complete

Project

TR12: A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis with Nalbuphine ER Tablets for the Treatment of Cough

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£20,357.00

Started

1 October 2019

Status

Complete

Project

An exploratory sub-study to protocol GLPG1690-CL-303 to assess lung function in patients with idiopathic pulmonary fibrosis, using hyperpolarized xenon magnetic resonance imaging

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£3,228.00

Started

1 November 2019

Status

Complete

Project

A multi-centre, real-world exploratory cohort study to evaluate cough frequency, severity, and impact on quality of life in patients with non-idiopathic pulmonary fibrosis interstitial lung disease.

Funder

Boehringer Ingelheim Limited

Grant

£2,044.00

Started

1 December 2022

Status

Complete

Co-investigator

Project

Funder

Grant

Started

Status

Project

MABEL: A Parallel Group, Double-blind, Randomised Placebo-controlled Trial Comparing The Efficacy And Cost effectiveness

Funder

NIHR National Institute for Health Research

Grant

£731,726.00

Started

1 March 2019

Status

Ongoing

Project

BREATHE: Breathlessness RElief AT HomE

Funder

NIHR National Institute for Health Research

Grant

£232,098.00

Started

1 April 2019

Status

Complete

Project

Development and publication of the booklet for the pulmonary fibrosis (disease with a degree of similarity to coronavirus disease).

Funder

Pulmonary Fibrosis Trust

Grant

£322.00

Started

1 November 2020

Status

Complete

Project

Updating (Reviewing and Printing) the Patient's Guide to Pulmonary Fibrosis.

Funder

Pulmonary Fibrosis Trust

Grant

£401.00

Started

1 November 2022

Status

Complete

Project

Study of the lung endothelium in idiopathic pulmonary fibrosis

Funder

00 University of Hull

Grant

£35,465.00

Started

1 September 2020

Status

Complete

Project

BETTER-B: BETter TreatmEnts for Refractory Breathlessness

Funder

EC European Commission

Grant

£56,859.00

Started

1 January 2019

Status

Complete

Postgraduate supervision

2016-2019 Ms Emma Welch, PhD (Hull York Medical School). Sir Jules Thorn Research Trust. Mechanisms and consequences of platelet activation in idiopathic pulmonary fibrosis. Lead supervisor

2016-2019 Ms Francesca Longhorne, PhD (Hull York Medical School). University of Hull/HYMS research studentship. Immunological mechanisms in pulmonary fibrosis. Lead supervisor

2013-2016 Mr James Thompson, PhD (Hull York Medical School). University of Hull/Hull York Medical School research studentship. Development of novel PET imaging tracers in pulmonary fibrosis. Lead supervisor

2012-2015 Mr Simon Fraser, PhD (Hull York Medical School/University of Hull), awarded 2017. University of Hull/HYMS research studentship. Immunological studies in sarcoidosis. Lead supervisor

2012-2015 Mr James Williamson, PhD (Hull York Medical School/University of Hull), awarded 2016. University of Hull/Hull York Medical School research studentship. The role of endothelial adhesins in leukocyte adhesion in an experimental model of pharmaceutical agent-induced pulmonary fibrosis. Lead supervisor

2008-2011 Ms Ai-Yen Chin, PhD (University of Hull/Renal Research Foundation/Respiratory Medicine), awarded 2013. Protease activated receptor-4 in lung and renal fibrosis. Lead supervisor

2008-2011 Ms Aikaterina Bazakou, MPhil (University of Hull), awarded 2013. Regulation of Fc receptor function. Lead supervisor2009-2011 Dr Michael Crooks, MD (University of Hull), awarded 2012. Platelet and endothelial function in pulmonary fibrosis. Lead supervisor

2008-2010 Dr Ahmed Fahim, MD (University of Hull), awarded 2011. Pathogenesis of idiopathic pulmonary fibrosis. Lead supervisor2010 Dr Chee Kay Cheung, MSc by research (Hull York Medical School), awarded 2011. PAR4 in renal fibrosis. Lead supervisor.

Top